drugset / Trial / NCT03105349
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 4 clinical trial to treat patients who have failed to treat with regimen based on an inhibitor of the NS5A
Timeline
- Start
- 2017-07-01
- Primary completion
- 2017-12
- Completion
- 2018-02
Outcome
Outcome not reported
Stopped: “No availability of investigational medication.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | — | — |
| Subject | Sofosbuvir | Small molecule | — | — |
| Subject | elbasvir/grazoprevir | Unknown | — | — |